|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.47 USD | +36.39% |
|
+20.86% | +38.03% |
| 09/05 | RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk | MT |
| 08/05 | Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000 | MT |
IGM Biosciences, Inc. provided sales guidance for full year 2022. The company estimates full year collaboration revenue of approximately $1 million related to the Sanofi agreement.
| 1st Jan change | Capi. | |
|---|---|---|
| +38.03% | 677M | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.96% | 21.97B | |
| -5.34% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
IGM BIOSCIENCES, INC. 
